Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07533942 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma

Name: A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma — clinical trial record (NCT07533942)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorJazz Pharmaceuticals

Started2026-07-16

View on ClinicalTrials.gov ↗

Amendment history

2026-07-29

Study Status, Outcome Measures, Contacts/Locations v1

Recruitment opened

Start dateestimated 2026-06-01→confirmed 2026-07-16

Secondary endpointsdetails revised at 13 of 13 entries

Study sitesdetails revised at 5 of 5 sites

2026-04-10

Original filing

Jazz Pharmaceuticals

34 trials monitored

See 1 trial at risk

This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.

Trial Details

NCT Number	NCT07533942
Lead Sponsor	Jazz Pharmaceuticals Collaborators: Chimerix, Inc.
Conditions	Meningioma
Enrollment	30 participants
Start Date	2026-07-16
Primary Completion	2028-10-25 (estimated)
Study Completion	2031-10-16 (estimated)
Updated on ClinicalTrials.gov	2026-07-30